EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis

Sarah L Ash iD, Rebecca Orha iD, Holly Mole iD, Meg Dinesh-Kumar iD, Steven P Lee, Frances K Turrell iD, Clare M Isacke iD

Journal for ImmunoTherapy of Cancer · 2024-02 · 12 (2) · e008608

DOI: 10.1136/jitc-2023-008608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 27.02.2024. Verfasst von Sarah L Ash und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Cancer Research, London, UK. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Breast Cancer Now.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Targeting of solid cancers with chimeric antigen receptor (CAR)-T cells is limited by the lack of suitable tumor-specific antigens and the immunosuppressive, desmoplastic tumor microenvironment that impedes CAR-T cell infiltration, activity and persistence. We hypothesized that targeting the endosialin (CD248) receptor, strongly expressed by tumor-associated pericytes and perivascular cancer-associated fibroblasts, would circumvent these challenges and offer an exciting antigen for CAR-T cell therapy due to the close proximity of target cells to the tumor vasculature, the limited endosialin expression in normal tissues and the lack of phenotype observed in endosialin knockout mice.

Methods

We generated endosialin-directed E3K CAR-T cells from three immunocompetent mouse strains, BALB/c, FVB/N and C57BL/6. E3K CAR-T cell composition (CD4 + /CD8 + ratio), activity in vitro against endosialin + and endosialin – cells, and expansion and activity in vivo in syngeneic tumor models as well as in tumor-naive healthy and wounded mice and tumor-bearing endosialin knockout mice was assessed.

Results

E3K CAR-T cells were active in vitro against both mouse and human endosialin + , but not endosialin – , cells. Adoptively transferred E3K CAR-T cells exhibited no activity in endosialin knockout mice, tumor-naive endosialin wildtype mice or in wound healing models, demonstrating an absence of off-target and on-target/off-tumor activity. By contrast, adoptive transfer of E3K CAR-T cells into BALB/c, FVB/N or C57BL/6 mice bearing syngeneic breast or lung cancer lines depleted target cells in the tumor stroma resulting in increased tumor necrosis, reduced tumor growth and a substantial impairment in metastatic outgrowth.

Conclusions

Together these data highlight endosialin as a viable antigen for CAR-T cell therapy and that targeting stromal cells closely associated with the tumor vasculature avoids CAR-T cells having to navigate the harsh immunosuppressive tumor microenvironment. Further, the ability of E3K CAR-T cells to recognize and target both mouse and human endosialin + cells makes a humanized and optimized E3K CAR a promising candidate for clinical development applicable to a broad range of solid tumor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansMiceAnimalsPericytesMice, Inbred C57BLT-LymphocytesMice, KnockoutTumor MicroenvironmentAntigens, NeoplasmAntigens, CD

Stichwörter der Autor:innen

Breast CancerChimeric antigen receptor - CARLung CancerTumor microenvironment - TME

Substanzen

Receptors, Chimeric AntigenCD248 protein, humanAntigens, NeoplasmAntigens, CDCD248 protein, mouse

Autor:innen und Institutionen

  • The Institute of Cancer Research, London, UK.
  • Department of Oncology, University of Lausanne, Lausanne, Switzerland.
  • University of Birmingham, Birmingham, UK.
  • The Institute of Cancer Research, London, UK clare.isacke@icr.ac.uk frances.turrell@manchester.ac.uk.
  • Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

ORCID-Profile: Sarah L Ash, Rebecca Orha, Holly Mole, Meg Dinesh-Kumar, Frances K Turrell, Clare M Isacke

Förderung

  • Cancer Research UK
  • Breast Cancer Now

Zitieren

APA

Ash, S. L., Orha, R., Mole, H., Dinesh-Kumar, M., Lee, S. P., Turrell, F. K., & Isacke, C. M. (2024). Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis. Journal for ImmunoTherapy of Cancer, 12(2), e008608. https://doi.org/10.1136/jitc-2023-008608

Vancouver

Ash SL, Orha R, Mole H, Dinesh-Kumar M, Lee SP, Turrell FK, et al. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis. Journal for ImmunoTherapy of Cancer. 2024;12(2):e008608. doi:10.1136/jitc-2023-008608

BibTeX
@article{Ash2024,
  author = {Ash, Sarah L and Orha, Rebecca and Mole, Holly and Dinesh-Kumar, Meg and Lee, Steven P and Turrell, Frances K and Isacke, Clare M},
  title = {Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {2},
  pages = {e008608},
  doi = {10.1136/jitc-2023-008608}
}
Kostenlos starten →